Search

Your search keyword '"Cesbron, Elise"' showing total 3 results
Start Over Author "Cesbron, Elise" Topic lupus erythematosus, cutaneous
3 results on '"Cesbron, Elise"'

1. Risk of thromboembolic events in patients treated with thalidomide for cutaneous lupus erythematosus: A multicenter retrospective study.

Author

Cesbron E, Bessis D, Jachiet M, Lipsker D, Cordel N, Bouaziz JD, Bagot M, Arnaud L, Barbaud A, Francès C, and Chasset F

Subjects
Adult, Age Distribution, Aged, Cohort Studies, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Follow-Up Studies, France, Hospitals, University, Humans, Immunosuppressive Agents therapeutic use, Incidence, Lupus Erythematosus, Cutaneous diagnosis, Male, Middle Aged, Retrospective Studies, Risk Assessment, Severity of Illness Index, Sex Distribution, Survival Rate, Thalidomide therapeutic use, Thromboembolism physiopathology, Immunosuppressive Agents adverse effects, Lupus Erythematosus, Cutaneous drug therapy, Thalidomide adverse effects, Thromboembolism chemically induced, Thromboembolism epidemiology
Published
2018
Full Text
View/download PDF

2. Efficacy and tolerance profile of thalidomide in cutaneous lupus erythematosus: A systematic review and meta-analysis.

Author

Chasset F, Tounsi T, Cesbron E, Barbaud A, Francès C, and Arnaud L

Subjects
Humans, Immunosuppressive Agents adverse effects, Peripheral Nervous System Diseases chemically induced, Recurrence, Thalidomide adverse effects, Thromboembolism chemically induced, Immunosuppressive Agents therapeutic use, Lupus Erythematosus, Cutaneous drug therapy, Thalidomide therapeutic use
Abstract

Background: Thalidomide has shown excellent results for severe cutaneous lupus erythematosus (CLE), but its prescription is limited by potentially severe adverse events., Objective: To assess the overall rate of response to thalidomide in CLE with respect to CLE subtypes and the occurrence rate of relevant adverse events on the basis of previously published studies., Methods: We performed a systematic review and meta-analysis of studies published in MEDLINE, Embase, and the Cochrane Library between 1965 and January 2017. The proportions of responders and rates of adverse events were extracted from individual studies and pooled using random effects or fixed models., Results: Among 548 patients from 21 included studies, the overall rate of response to thalidomide was 90% (95% confidence interval [CI], 85-94), with similar response rates between CLE subtypes. Conversely, the pooled rate of thalidomide withdrawal related to adverse events was 24% (95% CI, 14-35) including confirmed peripheral neuropathy in 16% (95% CI, 9-25) and thromboembolic events in 2% (95% CI, 1-3). The pooled rate of relapse after thalidomide withdrawal was 71% (95% CI, 65-77) compared with 34% (95% CI, 25-44) with a maintenance dose., Limitations: We found important statistical heterogeneity across included studies., Conclusion: Considering the frequent occurrence of adverse events, prescription of thalidomide should be restricted to patients with severely refractory CLE or who are at high risk for severe scarring., (Copyright © 2017 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.)

Published
2018
Full Text
View/download PDF

3. Risk of thromboembolic events in patients treated with thalidomide for cutaneous lupus erythematosus: A multicenter retrospective study

Author

Cesbron, Elise, Bessis, Didier, Jachiet, Marie, Lipsker, Dan, Cordel, Nadège, Bouaziz, Jean-David, Bagot, Martine, Arnaud, Laurent, Barbaud, Annick, Francès, Camille, chasset, françois, Étude des Maladies Systémiques en Dermatologie, EMSED, Service de dermatologie et allergologie [CHU Tenon], CHU Tenon [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Sorbonne Université (SU), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Pathogénèse et contrôle des infections chroniques (PCCI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Centre Hospitalier Universitaire de Montpellier (CHU Montpellier ), Service de Dermatologie [AP-HP Hôpital Saint-Louis], Hopital Saint-Louis [AP-HP] (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université Paris Diderot - Paris 7 (UPD7), CHU Strasbourg, Université de Strasbourg (UNISTRA), CHU Pointe-à-Pitre/Abymes [Guadeloupe], Université des Antilles (Pôle Guadeloupe), Université des Antilles (UA), Physiopathologie, Autoimmunité, maladies Neuromusculaires et THErapies Régénératrices (PANTHER), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de rhumatologie [Strasbourg], CHU Strasbourg-Hôpital de Hautepierre [Strasbourg], Immuno-Rhumatologie Moléculaire, and Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM)

Subjects
Adult, Male, medicine.medical_specialty, Dermatology, Risk Assessment, Severity of Illness Index, Drug Administration Schedule, Cohort Studies, Hospitals, University, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, Age Distribution, Thromboembolism, Severity of illness, Lupus Erythematosus, Cutaneous, Medicine, Humans, Sex Distribution, Survival rate, ComputingMilieux_MISCELLANEOUS, Aged, Retrospective Studies, 030203 arthritis & rheumatology, Lupus erythematosus, Dose-Response Relationship, Drug, business.industry, Incidence (epidemiology), Incidence, Retrospective cohort study, Middle Aged, medicine.disease, 3. Good health, Thalidomide, Survival Rate, Female, France, business, Risk assessment, Immunosuppressive Agents, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, Cohort study, medicine.drug, Follow-Up Studies
Abstract

International audience

Published
2018

Catalog

Books, media, physical & digital resources
See catalog results